Stock Financial Ratios and Split History

INVA / Innoviva, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,699.91
Enterprise Value ($M)2,411.84
Book Value ($M)-242.86
Book Value / Share-2.03
Price / Book-7.87
NCAV ($M)200.37
NCAV / Share1.67
Price / NCAV9.54
Income Statement (mra) ($M)
Net Income134.27
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio5.77
Current Ratio5.77
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding119,866,000
Common Shares Outstanding101,824,355
Preferred Stock Shares Outstanding0
Weighted Average Number Of Shares Outstanding Basic106,945,000
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.41
Return on Assets (ROA)0.35
Return on Equity (ROE)-0.38
Identifiers and Descriptors
Central Index Key (CIK)1080014
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Related CUSIPS
45781M951 45781M101

Split History

Stock splits are used by Innoviva, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

Related News Stories

10 Risky (But Rewarding) Small-Cap Stocks to Buy Now

2018-02-28 investorplace
The market was up 22% over the course of the past year, led by giants like, Inc. (NASDAQ:AMZN) and Facebook Inc (NASDAQ:FB), before the bottom finally fell out and investors’ fears for a correction materialized. (295-1)

New Strong Sell Stocks for February 21st

2018-02-21 zacks
Camtek Ltd. (CAMT - Free Report) is a metrology and inspection equipment, and software solutions provider. The Zacks Consensus Estimate for its current year earnings has been revised 10.2% downward over the last 30 days. (58-1)

Innoviva's (INVA) Management on Q4 2017 Results - Earnings Call Transcript

2018-02-09 seekingalpha
Ladies and gentlemen, good afternoon. At this time, I'd like to welcome everyone to the Innoviva Fourth Quarter 2017 Financial Results Webcast and Conference Call. During the presentation, all participants will be in a listen-only mode. A question-and-answer session will follow the company’s formal remarks. [Operator Instructions] Today's conference call is being recorded. (31-0)

AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

2018-01-29 zacks
AstraZeneca Plc (AZN - Free Report) announced positive top-line results from a phase III study evaluating its investigational triple combination therapy PT010 for the treatment of chronic obstructive pulmonary disease (COPD). (164-0)

10 Risky (But Rewarding) Small-Cap Stocks to Buy Now | InvestorPlace

2018-01-23 investorplace
With the market up 22% up over the course of the past year, led by giants like, Inc. (NASDAQ:AMZN) and Facebook, Inc. (NASDAQ:FB), investors might fear that a pullback is just around the corner. And maybe one is. (295-9)

CUSIP: 88338T104